Get the Stockscreener App
7.00
0.72%
0.05
After Hours:
6.95
-0.05
-0.71%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $7.00, with a volume of 1.57M.
It is up +0.72% in the last 24 hours and down -4.37% over the past month.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
See More
Previous Close:
$6.95
Open:
$7
24h Volume:
1.57M
Relative Volume:
0.50
Market Cap:
$497.87M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-4.2683
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
-0.85%
1M Performance:
-4.37%
6M Performance:
+10.76%
1Y Performance:
-28.57%
1-Day Range:
$6.9013
$7.135
1-Week Range:
$6.77
$7.42
52-Week Range:
$5.275
$14.84
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
7.00 | 497.87M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Sprout Social, Altimmune, Equinix, and Globe Life - GlobeNewswire
Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - GlobeNewswire Inc.
(ALT) Technical Pivots with Risk Controls - Stock Traders Daily
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times
Exclusive: Altimmune Management Reveals Strategic Roadmap at Major Biotech Conference - StockTitan
Exchange Traded Concepts LLC Lowers Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
JPMorgan Chase & Co. Sells 191,848 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
HC Wainwright Comments on Altimmune FY2029 Earnings - MarketBeat
HC Wainwright Forecasts Altimmune FY2029 Earnings - MarketBeat
Altimmune spikes after presenting data for obesity drug - MSN
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook - MSN
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com UK
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Altimmune's (ALT) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Long Term Trading Analysis for (ALT) - Stock Traders Daily
Is Altimmune (NASDAQ:ALT) In A Good Position To Invest In Growth? - Simply Wall St
Altimmune's SWOT analysis: pemvidutide stock shows promise in obesity, NASH markets - Investing.com
Altimmune (NASDAQ:ALT) Shares Gap UpTime to Buy? - MarketBeat
Altimmune (NASDAQ:ALT) Now Covered by Stifel Nicolaus - MarketBeat
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel initiates Altimmune stock at Buy on pemvidutide potential - Investing.com
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Geode Capital Management LLC Acquires 74,194 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Analyst Sees Major Growth for Biopharma With Weight-Loss Drug - Streetwise Reports
Barclays PLC Raises Stake in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Shares Down 5.9%Here's Why - MarketBeat
Altimmune Could Find A Partner For Its Phase 3 Exercise (NASDAQ:ALT) - Seeking Alpha
(ALT) Technical Data - Stock Traders Daily
Jim Cramer on Altimmune, Inc. (ALT): ‘Healthcare Is So Out Of Fashion’ - Insider Monkey
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate - Yahoo Finance
Altimmune, Inc. (NASDAQ:ALT) Shares Sold by State Street Corp - MarketBeat
Altimmune (NASDAQ:ALT) Stock Price Down 4.6%Should You Sell? - MarketBeat
Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds - MSN
Altimmune (ALT) Gains on Nasdaq Biotechnology Index Inclusion - GuruFocus.com
Why Altimmune Was Such a Robustly Healthy Stock on Thursday - MSN
Altimmune (NASDAQ:ALT) Trading Up 4.7%Here's Why - MarketBeat
Altimmune joins Nasdaq Biotechnology Index - Investing.com
Altimmune Joins Nasdaq Biotechnology Index, Gears Up for Pivotal MASH Drug Trial Data in 2025 - StockTitan
(ALT) Trading Report - Stock Traders Daily
Altimmune (NASDAQ:ALT) Stock Price Down 5.1%Should You Sell? - MarketBeat
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity stock outlook - Investing.com
Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News
Altimmune 2025: Redefining Obesity And MASH Treatment (NASDAQ:ALT) - Seeking Alpha
Virtu Financial LLC Makes New $674,000 Investment in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Shares Up 4.9%Still a Buy? - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Altimmune reports positive trial results for liver disease drug By Investing.com - Investing.com Nigeria
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):